(Q43037030)

12 November 2017

title

Response to peginterferon-alfa 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 2. (English)

1 reference

12 November 2017

1 reference

1 reference

16

Keiichi Fujiwara

1 reference

12 November 2017

Tatsuo Kanda

1

1 reference

12 November 2017

Fumio Imazeki

2

1 reference

12 November 2017

Ryosaku Azemoto

3

1 reference

12 November 2017

Yutaka Yonemitsu

4

1 reference

12 November 2017

Shigeru Mikami

5

1 reference

12 November 2017

Kazuhiko Kita

6

1 reference

12 November 2017

Motohide Takashi

7

1 reference

12 November 2017

Masahiko Sunaga

8

1 reference

12 November 2017

Shuang Wu

9

1 reference

12 November 2017

Shingo Nakamoto

10

1 reference

12 November 2017

Akinobu Tawada

11

1 reference

12 November 2017

Makoto Arai

12

1 reference

12 November 2017

Keizo Kato

13

1 reference

12 November 2017

Yu Yoshida

14

1 reference

12 November 2017

Yoshihiro Koma

15

1 reference

12 November 2017

Kenichi Fukai

17

1 reference

12 November 2017

Noriaki Suzuki

18

1 reference

12 November 2017

Osamu Yokosuka

19

1 reference

12 November 2017

publication date

22 May 2011

1 reference

Digestive Diseases and Sciences

12 November 2017

published in

1 reference

12 November 2017

volume

56

1 reference

12 November 2017

issue

11

1 reference

12 November 2017

page(s)

3335-3342

1 reference

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1750-7

Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1750-7

Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1750-7

Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1750-7

Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1750-7

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1750-7

Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1750-7

Sequence variability in the 5' non-coding region of hepatitis C virus: identification of a new virus type and restrictions on sequence diversity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1750-7

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1750-7

New antiviral therapies for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1750-7

Treatment of hepatitis C virus infection: updated Swedish Consensus recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1750-7

Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1750-7

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1750-7

Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1750-7

Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1750-7

Nonresponder patients with hepatitis C virus genotype 2/3 infection: a question of low systemic interferon concentrations?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1750-7

Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1750-7

Optimal therapy in hepatitis C virus genotypes 2 and 3 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1750-7

Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C.

21 January 2018

1 reference

12 December 2020

Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C.

1 reference

12 December 2020

Quantification of hepatitis C virus in patients treated with peginterferon-alfa 2a plus ribavirin treatment by COBAS TaqMan HCV test

1 reference

12 December 2020

Optimal therapy of hepatitis C.

1 reference

12 December 2020

High sustained virologic response rate after interferon monotherapy in Japanese hepatitis C patients with a low HCV RNA titer and/or HCV genotype 2. A prospective study

1 reference

12 December 2020

Significance of specific antibody assay for genotyping of hepatitis C virus

1 reference

12 December 2020

Ribavirin plasma concentration is a predictor of sustained virological response in patients treated for chronic hepatitis C virus genotype 2/3 infection

1 reference

12 December 2020

10.1007/S10620-011-1750-7

Identifiers

DOI

1 reference

12 November 2017

1 reference